ReviewEuropean journal of haematology2020
Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.
Review in European journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- A systematic review of health state utility values for older people with acute myeloid leukaemia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Geriatric assessment in older patients with a hematologic malignancy: a systematic review.Haematologica · 2020Pooled it
- Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.Blood advances · 2023Trial
- Long-term health-related quality of life and lifestyle behavior of patients with acute myeloid leukemia.The oncologist · 2026Article
- Nutrition and Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults (Aged ≥60): A Scoping Review.Journal of the Academy of Nutrition and Dietetics · 2025Article
- Review
- Myelodysplastic syndromes.Nature reviews. Disease primers · 2022Review
- Psychometric Properties of MD Anderson Symptoms Inventory for Acute Myeloid Leukemia Patients in Thailand.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- [Application of patient-reported-outcome in myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia.Blood cancer journal · 2022Article
- Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.Blood cancer journal · 2022Article
- Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists.Blood advances · 2022Article
- The anemia-independent impact of myelodysplastic syndromes on health-related quality of life.Annals of hematology · 2021Article
- A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS.Blood advances · 2021Article
- Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?International journal of environmental research and public health · 2021Review
- Blood cancer health disparities in the United States Hispanic population.Cold Spring Harbor molecular case studies · 2021Article
- Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.Clinical practice and epidemiology in mental health : CP & EMH · 2021Review
- A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.American journal of blood research · 2021Review
- Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.European journal of haematology · 2020Review
- Health Related Quality of Life in Patients with Onco-hematological Diseases.Clinical practice and epidemiology in mental health : CP & EMH · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
Abstract
objectivesThis study aims to describe the use of patient-reported outcome measures (PROMs) in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) studies and the PROMs landscape.
methodsA comprehensive literature review was performed in Medline/Embase (since 2000) and ClinicalTrials.gov (since 2013) to identify PROMs used in MDS and AML clinical studies. Additionally, PROMs included in approved drug labels since 2000 were reviewed.
resultsOverall, 112 different PROMs were used in 168 published MDS studies and 152 PROMs were used in 172 AML studies. From ClinicalTrials.gov, 16 different PROMs were used in 22 ongoing registered studies in MDS, and 24 were reported in 41 AML studies. The most frequently used PROMs were cancer-specific (eg, EORTC QLQ-C30, FACT-An) or generic (SF-36, EQ-5D) instruments, whereas MDS- and AML-specific instruments (eg, QUALMS and QOL-E in MDS; FACT-Leu and EORTC QLQ-Leu in AML) were used in a minority of studies. Two EMA-approved drugs for MDS included PROMs in their label. EORTC QLQ-C30 is by far the most frequently used cancer-specific PROM in both MDS and AML studies.
conclusionsThis research indicated an underuse of AML/MDS-specific PROMs for these two indications in clinical studies and labeling claims. However, AML/MDS-specific instruments in development might be considered in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.